To Compare the Safety and Efficacy of Intracameral Levofloxacin and Intracameral Cefazolin in Reducing Rates of Endophthalmitis Following Cataract Surgery.
Key facts
- Who runs it
- Tan Tock Seng Hospital
- Where
- Singapore2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Early phase 1
- People taking part
- 50 people enrolled
- Started
- 1 Jan 2022
- Ended
- 1 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Safety of intracameral levofloxacin in cataract surgery
- Use of intracameral cefazolin in cataract surgery
- Record updated
- 2 December 2024
Who can take part
- Age
- 50 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Aged ≥50 to <80 years
- Undergoing cataract surgery under the care of one of three study investigators, all of whom were consultant level cataract surgeons
- Only those with senile cataracts, assessed using the Lens Opacities Classification System III scale (LOCS III) and without features of complex cataracts were included
Who cannot take part
- Prior ocular trauma, pregnant, previous history of refractive, corneal or intraocular surgery, cornea endothelial cell count <1500/sqmm², concomitant ocular disease, allergy to penicillin, fluoroquinolone or cephalosporin, and abnormal biometric measurements
- <50 or >80 years old
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Patients with senile cataracts undergoing phacoemulsification were assigned to receive intracameral levofloxacin (0.1ml/0.5mg) or intracameral cefazolin (0.1ml/1mg). The primary endpoint was the occurrence of endophthalmitis during the 3 month follow-up period. Secondary endpoints included best-corrected visual acuity (BVCA), the presence of anterior chamber (AC) inflammation with grading of AC cells and presence of flare, along with intraocular pressure (IOP), corneal cell thickness (CCT), central foveal thickness (CFT) and cell density.
The 2 groups in the trial
- Safety of Intracameral levofloxacin in cataract surgeryTreatment being tested
Eligible and recruited patients are randomized to intracameral levofloxacin or intracameral cefazolin during cataract surgery
Treatment: Safety of intracameral levofloxacin in cataract surgery and Use of intracameral cefazolin in cataract surgery
- Use of intracameral cefazolin in cataract surgeryExisting treatment, for comparison
Eligible and recruited patients were randomized to intracameral levofloxacin or intracameral cefazolin during cataract surgery
Treatment: Safety of intracameral levofloxacin in cataract surgery and Use of intracameral cefazolin in cataract surgery
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Double-blind, Randomized Controlled Pilot Study Comparing the Safety and Efficacy of Intracameral Levofloxacin and Intracameral Cefazolin in Cataract Surgery
- Publications
- Record updated
- 2 December 2024